$13.15
-0.17-1.24%
Dern. MÀJ: Oct 29, 1:54 PM
Intellia Therapeutics (NTLA) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.80 | $-0.90 | $-0.97 | $-1.00 |
| Actual | $-0.80 | $-0.81 | $-0.83 | $-0.92 |
| Surprise | 0.00% | +10.0% | +14.4% | +8.00% |
| Revenue | ||||
| Estimate | $13.4M | $14.2M | $12.0M | $14.8M |
| Actual | $7.7M | $15.0M | $23.0M | $13.8M |
| Surprise | -43.0% | +6.34% | +91.1% | -6.63% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.79 | $-0.76 | $-0.85 | $-0.79 |
| Revenue | ||||
| Consensus | $9.8M | $18.5M | — | — |
| Trimestre Fiscal | Date de Déclaration | BPA Réel | BPA Estimé | Surprendre % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $-0.80 | $-0.80 | 0.00 % |
| Q1 | May 11, 2026 | $-0.81 | $-0.90 | 10.0 % |
| Q4 | Feb 26, 2026 | $-0.83 | $-0.97 | 14.4 % |
| Q3 | Nov 6, 2025 | $-0.92 | $-1.00 | 8.00 % |
| Trimestre Fiscal | Date de Déclaration | Revenu Réel | Revenu Estimé | Surprendre % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $7.66M | $13.45M | -43.0 % |
| Q1 | May 11, 2026 | $15.05M | $14.15M | 6.34 % |
| Q4 | Feb 26, 2026 | $23.02M | $12.04M | 91.1 % |
| Q3 | Nov 6, 2025 | $13.78M | $14.76M | -6.63 % |